LXEO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Lexeo Therapeutics, Inc. Common Stock

NASDAQ | LXEO

8.21

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 14, 2025)

$442.81M

Market Cap

-

P/E Ratio

-3.21

EPS

$11.30

52 Week High

$1.45

52 Week Low

HEALTHCARE

Sector

LXEO Chart

Recent Chart
Price Action

LXEO Technicals

Tags:

LXEO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2M
Total Revenue $0
Cost Of Revenue $2M
Costof Goods And Services Sold $2M
Operating Income -$106M
Selling General And Administrative $32M
Research And Development $74M
Operating Expenses $106M
Investment Income Net -
Net Interest Income $7.4M
Interest Income $7.6M
Interest Expense $114K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2M
Income Before Tax -$98M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$98M
Comprehensive Income Net Of Tax -
Ebit -$98M
Ebitda -$96M
Net Income -$98M

Revenue & Profitability

Earnings Performance

LXEO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $147M
Total Current Assets $126M
Cash And Cash Equivalents At Carrying Value $35M
Cash And Short Term Investments $35M
Inventory -
Current Net Receivables -
Total Non Current Assets $21M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $7M
Short Term Investments $87M
Other Current Assets $4.6M
Other Non Current Assets -
Total Liabilities $30M
Total Current Liabilities $23M
Current Accounts Payable $6.4M
Deferred Revenue -
Current Debt -
Short Term Debt $5.3M
Total Non Current Liabilities $7.3M
Capital Lease Obligations $9.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $9.9M
Other Current Liabilities $11M
Other Non Current Liabilities -
Total Shareholder Equity $117M
Treasury Stock -
Retained Earnings -$280M
Common Stock $3K
Common Stock Shares Outstanding $32M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$81M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2M
Capital Expenditures $481K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$94M
Cashflow From Financing $89M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$17K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$98M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2M
Total Revenue $0
Cost Of Revenue $2M
Costof Goods And Services Sold $2M
Operating Income -$106M
Selling General And Administrative $32M
Research And Development $74M
Operating Expenses $106M
Investment Income Net -
Net Interest Income $7.4M
Interest Income $7.6M
Interest Expense $114K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2M
Income Before Tax -$98M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$98M
Comprehensive Income Net Of Tax -
Ebit -$98M
Ebitda -$96M
Net Income -$98M

LXEO News

LXEO Profile

Lexeo Therapeutics, Inc. Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Lexeo Therapeutics, Inc. is a pioneering clinical-stage genetic medicine company based in New York, specializing in the development of innovative therapies for both hereditary and acquired diseases. With a robust pipeline of therapies leveraging advanced gene-editing technologies, Lexeo is positioned to address significant unmet medical needs and enhance patient outcomes. The company is committed to advancing its proprietary platforms to deliver next-generation treatments, firmly establishing itself as a key player in the evolving landscape of genetic medicine.

VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
BURU
-21.69%
$0.40
YYAI
-21.23%
$0.13
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+19.97%
$0.31
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
CAN
+13.81%
$1.73
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
LAES
+17.31%
$7.19
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
CRML
+20.74%
$28.10
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
NAK
+2.63%
$2.73
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
AREC
+30.09%
$6.47
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
ABAT
+5.16%
$9.69
IREN
+2.41%
$65.69
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
ONDS
-4.99%
$10.27
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
PLTD
-1.00%
$6.91
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
SLDP
+9.38%
$6.89
VHAI
+66.66%
$0.00
CGBS
-39.47%
$0.03
BITF
+28.33%
$5.39
UGRO
+71.96%
$0.63
BURU
-21.69%
$0.40
YYAI
-21.23%
$0.13
INTC
+2.33%
$37.22
QBTS
+23.01%
$40.61
SSKN
+48.00%
$2.27
ITP
+19.97%
$0.31
NVTS
+20.93%
$12.05
AXDX
-61.36%
$0.03
NVDA
-3.28%
$182.13
CAN
+13.81%
$1.73
EDHL
+79.75%
$0.89
BYND
-22.73%
$0.79
LAES
+17.31%
$7.19
MP
+21.34%
$95.06
PLUG
+0.38%
$3.91
IONQ
+16.19%
$82.09
MNTS
+30.76%
$1.87
CRML
+20.74%
$28.10
KDLY
-1.56%
$0.85
RGTI
-4.27%
$52.55
RMBL
+60.50%
$3.21
JDZG
+32.97%
$2.50
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AMZN
+1.71%
$220.07
NAK
+2.63%
$2.73
IONZ
+10.03%
$2.53
SRM
+53.27%
$10.30
UUUU
+3.70%
$24.65
AMD
+1.83%
$220.40
DNN
-0.81%
$3.05
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
TSLA
-2.60%
$424.55
DVLT
+7.57%
$1.82
WLGS
-5.57%
$0.04
ETHD
+11.40%
$3.70
TMQ
+10.62%
$6.56
GPUS
-9.48%
$0.38
UAMY
-0.26%
$16.66
ETWO
0.00%
$3.30
VZ
-0.25%
$39.75
NUAI
+35.36%
$3.18
USAR
-3.83%
$37.19
WULF
+8.50%
$15.19
TLRY
-3.84%
$1.62
AFMD
-34.94%
$0.18
CIFR
+0.19%
$20.38
ERIC
+17.07%
$9.56
ADAP
-15.26%
$0.15
WWR
+13.27%
$2.89
PLTR
+1.70%
$180.23
APLD
+5.70%
$36.19
OPI
-16.97%
$0.20
GWH
-9.09%
$8.22
AREC
+30.09%
$6.47
KLG
-9.05%
$13.35
NIO
-4.28%
$6.87
CORZ
+3.72%
$19.21
ABAT
+5.16%
$9.69
IREN
+2.41%
$65.69
GRYP
-10.38%
$1.38
GWAV
+89.77%
$16.14
SOFI
-0.46%
$27.01
SOUN
+3.78%
$19.86
MODV
-25.22%
$0.43
MARA
+3.65%
$20.98
ACHR
-5.12%
$12.11
BBD
+1.67%
$3.14
RGTZ
+5.16%
$9.77
ELAB
+83.43%
$9.55
FNB
+2.35%
$15.62
CLSK
+6.21%
$21.28
ATXS
+38.62%
$11.74
QS
-1.58%
$16.72
ONDS
-4.99%
$10.27
BMNR
-5.84%
$53.52
BMY
-0.95%
$43.54
NOK
+2.95%
$5.40
ASST
-5.54%
$1.02
F
+0.08%
$11.55
EXK
+10.96%
$8.50
PLTD
-1.00%
$6.91
BTBT
+0.75%
$4.03
VLY
+2.32%
$10.55
TBH
-48.33%
$1.24
DFLI
-1.68%
$1.54
NEHC
-9.61%
$2.35
SHOT
-74.37%
$0.39
EOSE
+2.05%
$17.39
RXRX
-3.79%
$5.32
GDXD
+1.06%
$0.74
NB
-3.88%
$10.88
ZAPP
-46.30%
$0.15
SLDP
+9.38%
$6.89
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.